Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Pluri (NASDAQ:PLUR) Head-To-Head Comparison

Pluri (NASDAQ:PLUR) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Pluri and Aurinia Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.02 million	12.85	-$23.82 million	($2.45)	-0.42
Aurinia Pharmaceuticals	$283.05 million	8.14	$287.20 million	$2.29	7.57

Aurinia Pharmaceuticals has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pluri and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pluri	-2,344.59%	N/A	-82.71%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

Volatility and Risk

Pluri has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Pluri and Aurinia Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1	0	0	0	1.00
Aurinia Pharmaceuticals	0	3	3	1	2.71

Aurinia Pharmaceuticals has a consensus price target of $17.75, indicating a potential upside of 2.45%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than Pluri.

Insider & Institutional Ownership

16.6% of Pluri shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 43.2% of Pluri shares are held by company insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Aurinia Pharmaceuticals beats Pluri on 13 of the 15 factors compared between the two stocks.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.